New Zealand’s medical cannabis sector is rapidly evolving, positioning itself as a major player on the global stage. Following the legalization of medical cannabis in December 2019 and the launch of the Medicinal Cannabis Scheme in April 2020, New Zealand has embraced commercial cultivation, research, manufacturing, and export of cannabinoid-based medicines. Market forecasts suggest that revenue could exceed $1.3 billion by 2028, indicating strong growth potential.
Data from the Ministry of Health shows a 68.4% increase in unapproved medicinal cannabis products containing CBD, THC, or both in 2024. Notably, products with THC and combined THC-CBD formulations have more than doubled in number compared to the previous year.
As part of their expansion strategy, a group of New Zealand companies is set to participate in Cannabis Europa this month, aiming to forge connections with European partners and explore new opportunities in the continent’s burgeoning market.
**Bluelab Holdings**, based in Tauranga, specializes in technology solutions for cannabis cultivation. The company provides precise measurement tools for pH, conductivity, and temperature to optimize growing conditions. CEO Jono Jones emphasizes that Europe’s growing focus on sustainability makes their products appealing to both regulators and consumers. Bluelab plans to establish regional sales support, starting in Germany, to better engage with local growers and adapt to cultural differences.
**Rua Bioscience**, located in Gisborne, is a trailblazer in medicinal cannabis with a focus on social impact. As a Māori-owned biotech firm, it integrates tradition with modern science. The company was the first in New Zealand to receive a medical cannabis cultivation license and has developed a strong research and breeding program. Rua Bioscience aims to support European supply chains by aligning its operations with EU-GMP standards, facilitating easier compliance for distributors. CEO Paul Naske notes that their Māori heritage adds unique value, making their products attractive to European brands focused on social responsibility.
With a goal of meeting the rising demand for high-potency cannabis in Germany and the Czech Republic, Rua’s cultivars consistently test above 23% THC, appealing to both patients and healthcare providers.
**Puro Limited**, New Zealand’s largest medical cannabis grower, focuses on organic production, having received a $13 million government grant to boost the organic cannabis industry. Operating in Marlborough, a region known for its wine production, Puro emphasizes sustainable farming practices. CEO Sank Macfarlane highlights the company’s commitment to high-quality, organic products that meet pharmaceutical standards. Puro aims to address the European market’s demand for consistent quality and regulatory trust, offering patients safe and effective options free from synthetic chemicals.
**Ora Pharm**, founded by Zoe Reece, is dedicated to improving health through sustainably grown cannabis. Operating from a state-of-the-art facility in Waikato, Ora Pharm adheres to rigorous quality standards set by both New Zealand and European regulations. The company also supports local cultivators by providing processing services to enhance quality and efficiency. Reece is enthusiastic about upcoming cannabis trials that could further demonstrate the therapeutic potential of cannabis for patients who do not respond to traditional treatments.
The collective ambition of these New Zealand companies showcases their readiness to enter the European market, capitalizing on a shared commitment to quality, sustainability, and innovation in cannabis cultivation. As they prepare for Cannabis Europa, they seek to leverage their unique strengths and collaborate with European counterparts to expand the global cannabis landscape.
English 
Spanish 
German 
Czech